98 related articles for article (PubMed ID: 5376451)
1. [Value of intravenous Melphalan in treatment of Kahler's disease].
Balmes A; Dauverchain J; Mandin A; Othoniel J; Vedel A
Mars Med; 1969; 106(6):505-8. PubMed ID: 5376451
[No Abstract] [Full Text] [Related]
2. [Use of intravenous melphalan in the treatment of Kahler's disease].
Balmes A; Dauverchain J; Othoniel J; Mandin A; Chavanette F
Presse Med (1893); 1971 May; 7(23):1072. PubMed ID: 5577947
[No Abstract] [Full Text] [Related]
3. [Comparative study of the melphalan and of the cyclophosphamide in the treatment of Kahler's disease].
Bontoux D; Chenbit D; Delbarre F
Therapeutique; 1971 Jan; 47(1):27-32. PubMed ID: 5572915
[No Abstract] [Full Text] [Related]
4. [Prognosis of Kahler's disease in patients treated and not treated with alkylating agents (apropos of 45 cases)].
Saporta L; Hugon C; Rondier J; Bontoux D; Delbarre F
Rev Rhum Mal Osteoartic; 1972 Jan; 39(1):11-8. PubMed ID: 5079686
[No Abstract] [Full Text] [Related]
5. [High-dose melphalan in patients with multiple myeloma].
Moreau P; Le Bonniec M; Harousseau JL
Bull Cancer; 1999 Mar; 86(3):283-8. PubMed ID: 10210762
[TBL] [Abstract][Full Text] [Related]
6. [Skin lesions as a rare initial symptom of Kahler's disease].
van Tol KM; Fedder G
Ned Tijdschr Geneeskd; 1994 Mar; 138(10):526-8. PubMed ID: 8139713
[TBL] [Abstract][Full Text] [Related]
7. [Ophthalmoplegia revealing Kahler's disease].
Ardouin M; Urvoy M; Eon JY; Le Blay R
Bull Soc Ophtalmol Fr; 1978 Dec; 78(12):897-9. PubMed ID: 755570
[No Abstract] [Full Text] [Related]
8. [Ulcero-necrotic purpura revealing Kahler's disease, with macroglobulinemia].
Bureau Y; Barrière H; Senelar R; Litoux P; Bureau B
Bull Soc Fr Dermatol Syphiligr; 1967; 74(4):495-8. PubMed ID: 4967360
[No Abstract] [Full Text] [Related]
9. Intermediate-dose (25mg/m2) IV melphalan for multiple myeloma with renal failure.
Vigneau C; Ardiet C; Bret M; Laville M; Fiere D; Tranchand B; Fouque D
J Nephrol; 2002; 15(6):684-9. PubMed ID: 12495285
[TBL] [Abstract][Full Text] [Related]
10. [Amylosis of the nerve in Kahler's disease].
Buge A; Escourolle R; Poisson M; Rancurel G; Hauw JJ
Ann Med Interne (Paris); 1974 Apr; 125(4):359-63. PubMed ID: 4433098
[No Abstract] [Full Text] [Related]
11. Pharmacology of intravenous melphalan in patients with multiple myeloma.
Brox L; Birkett L; Belch A
Cancer Treat Rev; 1979 Jun; 6 Suppl():27-32. PubMed ID: 498169
[No Abstract] [Full Text] [Related]
12. Short course intermediate dose intravenous melphalan therapy in myeloma--relation to early emergence of drug resistance (phase II study).
Sviland L; Leggat H; Harris AL; Bird G; Proctor SJ
Acta Haematol; 1987; 78(4):233-8. PubMed ID: 3122488
[TBL] [Abstract][Full Text] [Related]
13. [TREATMENT OF KAHLER'S DISEASE WITH MELPHALAN].
DIK HJ; DE VRIES SI
Ned Tijdschr Geneeskd; 1964 Jul; 108():1343-8. PubMed ID: 14183530
[No Abstract] [Full Text] [Related]
14. Melphalan and its role in the management of patients with multiple myeloma.
Falco P; Bringhen S; Avonto I; Gay F; Morabito F; Boccadoro M; Palumbo A
Expert Rev Anticancer Ther; 2007 Jul; 7(7):945-57. PubMed ID: 17627453
[TBL] [Abstract][Full Text] [Related]
15. [Clinical study on chemotherapy for multiple myeloma. Part II: Prognostic factors of treatment with prednisolone and sequential melphalan and ifosfamide: MIP therapy].
Sezaki T; Ishii H; Adachi T; Takahashi I; Ohnoshi T; Kimura I
Rinsho Ketsueki; 1983 Apr; 24(4):433-9. PubMed ID: 6887543
[No Abstract] [Full Text] [Related]
16. [Maintenance therapy with low-dose of melphalan in multiple myeloma (author's transl)].
Hirasawa Y; Nagaoka T; Kuto F; Tokuhiro H; Kikawada R
Rinsho Ketsueki; 1980 Nov; 21(11):1646-54. PubMed ID: 7206225
[No Abstract] [Full Text] [Related]
17. Comparison of high-dose melphalan with a more intensive regimen of thiotepa, busulfan, and cyclophosphamide for patients with multiple myeloma.
Anagnostopoulos A; Aleman A; Ayers G; Donato M; Champlin R; Weber D; Alexanian R; Giralt S
Cancer; 2004 Jun; 100(12):2607-12. PubMed ID: 15197803
[TBL] [Abstract][Full Text] [Related]
18. [Fluoride-therapy in Kahler's disease and osteoporosis].
Dalderup CB
Ned Tijdschr Geneeskd; 1970 May; 114(19):816-7. PubMed ID: 5424729
[No Abstract] [Full Text] [Related]
19. Effectiveness of two-stage treatment of multiple myeloma with melphalan and with melphalan in combination with cyclophosphamide, carmustine, vincristine and prednisone.
Snigurowicz J; Kraj M; Rostkowska J; Maj S; Mariańska B; Mendek E; Roszkowski S; Kilian Z; Kołakowski L
Arch Immunol Ther Exp (Warsz); 1981; 29(2):145-53. PubMed ID: 7030265
[No Abstract] [Full Text] [Related]
20. [Primary treatment results in myeloma disease using a cytostatic preparation].
Iavorkovskiĭ LI; Soloveĭ DIa; Udris OIu; Riauzova LIu; Bliumental' RIa
Probl Gematol Pereliv Krovi; 1981 Aug; 26(8):36-40. PubMed ID: 7301789
[No Abstract] [Full Text] [Related]
[Next] [New Search]
